Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract

Seok Jin Kim, Byung Soo Kim, Chul Won Choi, Hee Yun Seo, Hye Ryoung Seol, Hwa Jung Sung, In Sun Kim, Chul Yong Kim, Kwang-Yoon Jung, Jun Suk Kim

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.

Original languageEnglish
Pages (from-to)1265-1273
Number of pages9
JournalLeukemia and Lymphoma
Volume47
Issue number7
DOIs
Publication statusPublished - 2006 Jul 1

Fingerprint

Extranodal NK-T-Cell Lymphoma
Drug Therapy
Adjuvant Radiotherapy
Nasal Cavity
Survival
Nasopharynx
Chemoradiotherapy
Disease-Free Survival
Confidence Intervals
Lymphoma
Radiotherapy

Keywords

  • Chemotherapy
  • Extranodal lymphoma
  • NK/T cell
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. / Kim, Seok Jin; Kim, Byung Soo; Choi, Chul Won; Seo, Hee Yun; Seol, Hye Ryoung; Sung, Hwa Jung; Kim, In Sun; Kim, Chul Yong; Jung, Kwang-Yoon; Kim, Jun Suk.

In: Leukemia and Lymphoma, Vol. 47, No. 7, 01.07.2006, p. 1265-1273.

Research output: Contribution to journalArticle

@article{2191d85ca80a4094b36e989c1e28fe1c,
title = "Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract",
abstract = "We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4{\%} (29/43) and the complete remission (CR) rate was 44.2{\%} (19/43). Median overall and disease-free survival was 26.87 months [95{\%} confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95{\%} CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.",
keywords = "Chemotherapy, Extranodal lymphoma, NK/T cell, Radiotherapy",
author = "Kim, {Seok Jin} and Kim, {Byung Soo} and Choi, {Chul Won} and Seo, {Hee Yun} and Seol, {Hye Ryoung} and Sung, {Hwa Jung} and Kim, {In Sun} and Kim, {Chul Yong} and Kwang-Yoon Jung and Kim, {Jun Suk}",
year = "2006",
month = "7",
day = "1",
doi = "10.1080/10428190600565651",
language = "English",
volume = "47",
pages = "1265--1273",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract

AU - Kim, Seok Jin

AU - Kim, Byung Soo

AU - Choi, Chul Won

AU - Seo, Hee Yun

AU - Seol, Hye Ryoung

AU - Sung, Hwa Jung

AU - Kim, In Sun

AU - Kim, Chul Yong

AU - Jung, Kwang-Yoon

AU - Kim, Jun Suk

PY - 2006/7/1

Y1 - 2006/7/1

N2 - We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.

AB - We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.

KW - Chemotherapy

KW - Extranodal lymphoma

KW - NK/T cell

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33747698361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747698361&partnerID=8YFLogxK

U2 - 10.1080/10428190600565651

DO - 10.1080/10428190600565651

M3 - Article

VL - 47

SP - 1265

EP - 1273

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -